BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
And the truth is that that's not going to be the case because there's a lot of patients that, you know, refuse cisplatinum-based chemotherapy, are not eligible for cisplatinum-based chemotherapy, are not going to get any neoadjuvant chemotherapy. About, you know, half of our patients in the ambassador study got no neoadjuvant chemotherapy.
0
💬
0
Comments
Log in to comment.
There are no comments yet.